大家好，

2017 台灣肝癌醫學會國際教育研討會

Management of HepatocellularCarcinoma: Beyond the limits

日期：2017/12/17 08:30~16:25

地點：張榮發國際會議中心1001會議室

注意：12/17當天早上 06：30~08：30 有交通管制，建議搭乘大眾捷運系統，如欲自行開車前來者，可由仁愛路南側車道入場(請詳見附件交通管制資訊圖)

本次活動內容豐富，

特邀請日本、韓國、新加坡外賓及國衛院貴賓擔任講師，並有會員壁報展示、及 招商攤位等安排

關於本次國際研討會外賓演講內容創新及要點如下:

※Is Anatomical Pathology in HCC Still Relevant?

主講者: Prof. Michiie Sakamoto (09:20-09:50)

一、Multi-dimensional pathologic diagnosis of HCC

二、Immunohistochemical molecular subclassification of HCCand its possible clinical application

三、Quantitative digital image analysis and its possibleclinical application

※ TheraSphere experience and data overview

主講者: Prof. Do Young Kim (13:00-13:25)

一、TheraSphere is a glass-based, Yttrium-90 loadedinterventional material to treat patients with intermediate or advanced stagehepatocellular carcinoma (HCC).

二、 One of the main purporse of using TheraSphere in HCC isto have an opportunity of downstaging and resection/liver transplantation.

※ Multidimensional Analysis on ImmuneMicroenvironment in HCC-Biomarker and Y-90 TARE Therapeutic Discovery

What are the new findings?

主講人:Dr.Valerie Chew(13:25-13:55)

一、 By time-of-flight mass cytometry and next-generationsequencing, we detected immune activation in the local microenvironment ofY90-RE treated tumors and infiltration of multiple immune subsets.

二、 Immunomonitoring of peripheral blood before and after Y90-REidentified systemic immune activation, particularly in patients showingsustained therapeutic response to Y90-RE.

三、 Systemic immune profiles of the pre treatment peripheralblood could be used as a predictive biomarker for a sustained therapeutic responseto Y90-RE.

How might it impact on clinicalpractice in the foreseeable future?

一、 Immune activation of the local HCC microenvironmentafter Y90-RE suggests that combining immunotherapy with checkpoint-inhibitorscould improve tumor response and clinical outcomes.

二、 A prediction model to select patients who are mostlikely to positively respond to Y90-RE could be used in the future clinicalsetting.

※HCC carcinogenesis – microbiota and NAFLD

主講者: 高承源 教授(09:50-10:20)

一、DUSP6 is a novel regulator for intestinal microbiota.

二、 Lean-associated microbiota is a new prevention strategyfor obesity 
and its related diseases such as NAFLD.

三、、Inhibiting DUSP6 could serve as a new therapeutictreatment of 
chronic liver diseases.

另有國內講師內容創新及要點，請詳見附加檔案

歡迎各位踴躍參加。

如有問題請聯繫學會秘書處 tlcamail97@gmail.com

※議程表請參考附件